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Background: Acute myeloid leukemia (AML) comprises a spectrum of myeloid malignancies which are often
associated with distinct chromosomal abnormalities, and the analysis of such abnormalities provides us with
important information for disease classification, treatment selection and prognosis. Some chromosomal
abnormalities albeit recurrent are rare such as tetrasomy 8 or isochromosome 5p. In addition, erratic chromosomal
rearrangements may occur in AML, sometimes unbalanced and also accompanied by other abnormalities.
Knowledge on the contribution of rare abnormalities to AML disease, progression and prognosis is limited.
Here we report a unique case of acute monoblastic leukemia with gain of i(5)(p10), tetrasomy 8, an unbalanced
translocation der(19)t(17;19)(q23;p13.3) and mutated NPM1.
Results: Bone marrow cells were examined by conventional karyotyping, fluorescence in situ hybridization (FISH)
and mutation analysis at diagnosis and follow-up. At diagnosis we detected trisomy 8, an unbalanced translocation
der(19)t(17;19)(q23;p13.3) and mutated NPM1. During the course of the disease we observed clonal evolution with
gain of i(5)(p10), tetrasomy 8 and eventually duplication of der(19)t(17;19)(q23;p13.3). By using the der(19)t(17;19) as
clonal marker, we found that i(5)(p10) and tetrasomy 8 were secondary genetic events and that tetrasomy 8 had
clonally evolved from trisomy 8.
Conclusions: This case of acute monoblastic leukemia presents a combination of rare chromosomal abnormalities
including the unbalanced translocation der(19)t(17;19)(q23;p13.3), hitherto un-reported in AML. In addition, our case
supports the hypothesis of a step-wise clonal evolution from trisomy 8 to tetrasomy 8 in AML. Reporting and
collecting data of rare chromosomal abnormalities will add information to AML disease, progression and prognosis,
and may eventually translate to improved patient management.
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Acute myeloid leukemia (AML) comprises a spectrum of
hematologic malignancies with variable outcomes. A
hallmark of AML is maturation arrest of myeloid cells,
which accumulate in the peripheral blood and bone mar-
row. The un-differentiated myeloid cells show chromo-
somal abnormalities in about 55% of cases of adult AML
[1]. Some of these abnormalities, e.g. translocations are
recurrent and are used for disease classification [1,2].
Cytogenetics has become mandatory for the diagnosis
of AML according to the 2008 revision of the World
Health Organization (WHO) classification of tumors of
hematopoietic and lymphoid tissues [2]. Cytogenetic
analyses complemented with molecular methods and
mutation detection are useful for guiding treatment, for
monitoring residual disease and for providing prognostic
information towards clinical outcomes [3].
Trisomy 8 either as a sole or as an additional abnor-
mality is the most common among numerical abnormal-
ities associated with AML [4]. In contrast, tetrasomy 8 is
relatively rare and reported in a few cases in AML, only
[5-9]. Tetrasomy 8 seems to be associated with poor
prognosis [5,8]. A clonal relationship between trisomy 8
and tetrasomy 8 has been suggested, however, hardly
ever followed up in the cases described [8-10].
Gain of an isochromosome of the short arm of chromo-
some 5, i.e. i(5)(p10), represents a very rare recurrent abnor-
mality in AML [11,12]. To date only few cases have been
described (Table 1). The presence of i(5)(p10) seems to con-
comitantly occur with further abnormalities, sometimes in
the context of complex karyotypes [13]. In most cases re-
sponse to chemotherapy was reportedly poor [11-13].
Recurrent translocations in AML are typically balanced
and are often associated with a favorable prognosis. Erratic
chromosomal rearrangements may occur in AML, some-
times unbalanced and also accompanied by other abnormal-
ities. They are thought to contribute to disease progression
and are usually associated with poorer prognosis [3].
We present a unique case of AML with gain of i(5)
(p10), tetrasomy 8, unbalanced translocation der(19)t
(17;19)(q23;p13.3) and NPM1 mutation. By following the
course of the disease we show that gain of i(5)(p10)
and tetrasomy 8 represent secondary events in this
case and that tetrasomy 8 has clonally evolved from
trisomy 8.
Case presentation
In June 2011 a 64 year old male patient was admitted to
our hospital with recurrent epistaxis and ecchymosis. The
diagnosis of AML, in this case acute monoblastic
leukemia, was established. As the patient was not eligible
for bone marrow transplantation due to comorbidities, in-
duction therapy (7+3) with daunorubicin and cytarabine
followed by three cycles of consolidation treatment withhigh-dose cytarabine was administered and led to
complete hematologic and cytogenetic remission. A first
relapse occurred 14 months thereafter, which was treated
with induction therapy as before and, again, resulted to
complete remission. At 19 months a second relapse oc-
curred with additional infiltration of inguinal lymph nodes
and the skin. In January 2013 induction treatment with
cisplatin, gemcitabine and dexamethasone was adminis-
tered, which resulted in hematologic and partial cytogen-
etic remission at four month thereafter. In July 2013 the
patient vastly relapsed and passed away despite of contin-
ued consolidation therapy.
Results
At diagnosis conventional cytogenetics revealed the fol-
lowing karyotype: 47,XY,+8,add(19)(p13)[5]/46,XY[15].
The initial karyotype was defined more precisely with
multicolor fluorescence in situ hybridization (24X-FISH)
analysis, which yielded to the following karyotype: 47,
XY,+8,der(19)t(17;19)(q23;p13.3)[6]/46,XY[19]. At first
relapse a marked clonal evolution had occurred with
gain of isochromosome 5p and tetrasomy 8. The evolved
karyotype was determined as: 49,XY,+i(5)(p10),+8,+8,der
(19)t(17;19)(q23;p13.3)[7]/46,XY[14] (Figure 1). At sec-
ond relapse cytogenetic analysis showed a duplication of
the derivative chromosome 19 with loss of the normal
chromosome 19 (Figures 1 and 2A). In addition, a second
line was detected with trisomy 8, monosomy 13, der(19)t
(17;19) and 3 marker chromosomes, however, no i(5)(p10).
Triple-color metaphase- and interphase-FISH analysis
with a probe mixture for chromosome 8 centromers
and for chromosome 5p/5q complemented by 24X-
FISH analysis confirmed the respective abnormalities
(Figures 2B and 3). In order to narrow the breakpoints
of der(19)t(17;19), metaphase-FISH with an E2A specific
break-apart probe (D19S883) was used. Fusion signals were
observed on both normal and derivative chromosomes 19,
which indicated that the breakpoint on chromosome 19
ought to be located distal from the E2A gene locus
(Figure 4). The final karyotype was determined as: 49,XY,+i
(5)(p10),+8,+8,der(19)t(17;19)(q23;p13.3)x2[16]/49,XY,+8,-13,
der(19)t(17;19)(q23;p13.3),+3mar[4]/46,XY[2] (Figure 1).
The mutation analysis for NPM1 and FLT3 revealed
the NPM1-mutation c.959_960insCAGA and no FLT3
internal tandem duplication, respectively. This was also
obtained at relapses, and the NPM1 mutation was con-
served over the entire course of the disease.
At diagnosis the bone marrow aspirate showed 81%
monoblasts which stained positive for HLA-DR, CD33,
CD56, CD36, CD64, and negative for MPO, Tdt and
CD117, and the CBC was as follows: WBC 26.7 G/L
(47% blasts), Hgb 14.1 g/dl, and platelets 56 G/L. The
immunophenotyping and the cytological analysis were
consistent with acute monoblastic leukemia.
Table 1 Cases of myeloid malignancies with presence or gain of i(5)(p10) described in the literature
Case FAB type Karyotype +i(5)(p10) +8 References
1 AML-M1 47,XX,t(1;19)(p22;q13),del(2)(q33),del(3)(q21),+i(5)(p10),add(6)(p2?3) + Choi et al., 2007 [14]





+ Herry et al., 2007 [16]
Herry et al., 2010 [13]
4 AML-M2 46,XY,i(5)(p10),+der(12)t(1;12)(p11;p13),-13,-17,?add(22)(q13),+der(?)t(?;13)(?;q12)/47,idem,
del(1)(q11),+mar/47,idem,add(8)(q22),+mar
Tamura et al., 1995 [17]
5 AML-M3 47,XX,+i(5)(p10),ins(15;17)(q22;q21q21)/48,idem,+9 + Goldschmidt et al., 2010 [18]
6 AML-M4 47,XY,+8/47,XY,+i(5)(p10)/48,XY,+i(5)(p10),+8 + + Panani, 2006 [12]
7 AML-M4 43-45,XY,add(2)(p?21),i(5)(p10),-7,+8,-12,-16,-17,add(17)(p11),+1-3mar,inc + El Rifai, 1997 [19]
8 AML-M5 46,XX,t(6;14)(p12;q32),t(8;16)(p11;p13)/45,idem,-10/47,idem,+i(5)(p10) + Schmidt et al., 2004 [20]
9 AML-M5 46,X,del(Y)(q12),+der(2)t(2;14)(p11;q11),+i(5)(p10),+8,del(9)(q13),t(9;10)(q13;p11),del(10)(p11),-13,-14 + + Yunis et al., 1984 [21]
10 AML-M5a 47,XX,+i(5)(p10),t(8;16)(p11;p13) + Gervais et al., 2008 [22]
11 AML-M5a 48,XX,+i(5)(p10),+8 + + Schoch et al., 2001 [11]
12 AML-M5a 48,XX,+i(5)(p10),+8 + + Schoch et al., 2001 [11]
13 AML-M5a 48,XX,+i(5)(p10),+8,der(14)t(1;14)(q11;p11) + + Schoch et al., 2001 [11]
14 AML-M5b 50,XY,+der(5)t(1;5)(p13;q11),+i(5)(p10),add(6)(q25),+8,+der(8)t(8;14)(p11;q11),-14,del(17)(p11),+20 + + Slovak et al., 1991 [23]
15 AML-M6 46,XY,i(5)(p10),-10,add(12)(p?),-13,-14,-15,+4mar/46,XY,i(5),-6,-7,-17,-19, +rx3,+mar Herry et al., 2010 [13]
16 s-AMLb 48,XY,+1,der(1;13)(q10;q10),+i(5)(p10),+8 + + Flach et al., 2011 [24]
17 MDS 46,XX,i(5)(p10) Douet-Guilbert et al., 2011 [25]
18 MDS 46,XY,i(5)(p10),+8 + Jimenez-Souza et al., 2010 [26]
19 RAEB-1 46-48,XX,i(5)(p10),+6,add(6)(p?)x2,-7,add(9),add(14)(p?),+mar Lessard et al., 2007 [27]
20 RARS 47,XY,i(5)(p10),del(12)(p11),+i(12)(p10) Christodoulou et al., 2004 [28]
21 RCMD 44,X,-Y,i(5)(p10),inc Reddi et al., 2012 [29]
22 RCMD 46,XX,i(5)(p10),add(6)(p?),?i(9)(p?),add(14)(p10)/47,idem,+add(6) Herry et al., 2010 [13]
23 CML 47,XX,+X,der(1)t(1;5)(q36;q11),t(3;9;22;12)(q12;q34;q11;p13),-5,i(5)(p10),+8 + Markovic et al., 2000 [30]
s-AML, secondary acute myeloid leukemia; MDS, myelodysplastic syndrome; RAEB-1, refractory anemia with excess blasts-1; RARS, refractory anemia with ring sideroblasts; RCMD, refractory cytopenia with
multilineage dysplasia.
Bold letters highlight gain of isochromosome 5p and/or trisomy 8.
aThis case was reported by Herry et al. as patient 16 in 2007 [16] and as patient 5 in 2010 [13].
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Figure 1 Partial karyograms of clonal evolution. GTG-banded partial karyograms of all the involved chromosomes show the step-wise clonal
evolution from trisomy 8 to tetrasomy 8, gain of i(5)(p10) and derivative chromosome(s) 19 in the predominant sideline 1 at diagnosis, at first and
second relapse (upper panel). The lower panel depicts sideline 2 with trisomy 8, monosomy 13, a derivative chromosome 19 and three marker
chromosomes (second relapse). Note, no other aberrant clones have been detected at the respective time points.
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We described a case of acute monoblastic leukemia with
a unique combination of rare aberrations, i.e. gain of i(5)
(p10), tetrasomy 8, der(19)t(17;19)(q23;p13.3) and NPM1
mutation. To the best of our knowledge such a case has
not been reported previously.
In myeloid malignancies the occurrence of i(5)(p10) is
very rare and to date only 23 cases have been reported in
the literature (Table 1). The occurrence of i(5)(p10) was
described in 16 cases of AML, in 6 cases of MDS and in
one case of CML. Interestingly, gain of i(5)(p10), which re-
sults to a supernumerary chromosome 5, has exclusively
been reported in only 12 cases of AML, however, not in
MDS (Table 1). In 8 of the 12 cases with AML, i(5)(p10)
was accompanied by trisomy 8. In 7 of the 12 cases the
cells were of monoblastic/monocytic lineage (FAB M5).
The gain of i(5)(p10) resulted to tetrasomy 5p and disomyBA
Figure 2 GTG-banded karyotype and multicolor-FISH image at second
(p10), tetrasomy 8 and two derivative chromosomes 19. (B) Multicolor-FISH
unbalanced der(19)t(17;19). Arrows point to chromosomal abnormalities.5q, which was also observed in our case. In contrast, in
the cases with MDS (6 cases) and in other cases of AML
(4 cases) an i(5)(p10) replaced a normal chromosome 5
and, thus, led to trisomy 5p and monosomy 5q, perhaps
similar to a 5q- syndrome [13,25]. It is not clear, whether
these differences translate into differing phenotypes of the
diseases, as e.g. the cytological pattern is not completely
consistent in the cases described (Table 1). With two ex-
ceptions, i(5)(p10) was always observed in the context of
at least one other chromosomal abnormality, often in the
context of a complex karyotype (Table 1). Thus, i(5)(p10)
may represent a secondary cytogenetic event in the major-
ity of cases [11,13]. Our case supports this notion, since
gain of i(5)(p10) was not detected at diagnosis but was ob-
served in the wake of clonal evolution.
In the past, the incidence of i(5)(p10) could have been
underestimated by conventional G-banding as i(5)(p10)relapse. (A) The predominant aberrant subclone 1 shows gain of i(5)







Figure 3 FISH analysis using locus specific probes for chromosome 5p/5q and a centromer enumeration probe for the identification of
chromosome 8. Hybridization signals on an inverted DAPI counterstain metaphase spread show four blue signals indicative of tetrasomy 8, two
green signals on the supernumerary isochromosome 5p and two green and two red signals on the normal chromosomes 5. The insert shows a
representative interphase-FISH image of sideline 1/subclone 1 with the signal pattern of two red and four green dots (arrow-heads) indicating
gain of i(5)(p10) and four blue dots indicating tetrasomy 8 (arrows).
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in patients with MDS or AML. By using locus specific
probes towards 5p and 5q, FISH analysis allowed clear
discrimination between 5q- and i(5)(p10) both on meta-
phases and on interphase nuclei (Figure 3). This ap-
proach is useful not only in this case but also in the
routine diagnostic work-up of other cases.
Tetrasomy 8 has been reported in about 120 cases to
date [5]. It was observed mostly in AML of monocytic/A B
19
Figure 4 Analysis of the derivative chromosome 19. (A) Partial
GTG-banded karyogram showing a normal and a derivative
chromosome 19 (left- and right-hand side, respectively). The arrow
points to the additive band from 17q23. (B) Metaphase-FISH analysis
using the E2A gene specific break-apart probe (green, D19S883; red,
RH98588), which shows two normal fusion signals on both
chromosomes. The arrow points to the additive chromosomal
material on the derivative chromosome 19, which is illuminated by
the DAPI counterstain.monoblastic lineage, less frequently in MDS and very
rarely in MPD [5]. In the cases described the clone with
tetrasomy 8 was often seen in the presence of trisomy 8,
which favoured the hypothesis of a stepwise clonal evo-
lution by consecutive mitotic non-disjunctions from di-
somy 8 to trisomy 8 and to tetrasomy 8 or polysomy 8
[5,6,8]. Alternatively, tetrasomy 8 may evolve from sim-
ultaneous non-disjunction of both homologous chromo-
somes during a single cell division [8]. In our case clonal
evolution was monitored at three consecutive timepoints
by using the derivative chromosome 19 as clonal marker.
Thus, we demonstrated that tetrasomy 8 has evolved
from trisomy 8. Clonal evolution of tetrasomy 8 in AML
was previously reported in two cases, only. The one case
by Kameoka et al. was a MDS with trisomy 8 as the sole
abnormality, and when progression into AML occurred,
tetrasomy 8 was found [9]. A chromosomal marker was
not available as clonal control. In the other case by
Takahashi et al. AML showed the translocation t(9;11)
(p22;q23) and trisomy 8 at diagnosis [10]. During clonal
evolution tetrasomy 8 was detected and the t(9;11)(p22;
q23) served as clonal control. Together with our case
these findings support the hypothesis that tetrasomy 8
usually evolves stepwise by consecutive non-disjunctions
of chromosome 8 in AML [8].
Apart from trisomy 8 our case presented with an un-
balanced translocation der(19)t(17;19)(q23;p13.3) at
diagnosis. Although both breakpoint regions (17q23 and
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ous translocations and other aberrations in hematologic
malignancies, a literature search (PubMed and Mitelman
database) on t(17;19)(q23;p13) in AML did not return a
single hit, which suggests that the observed derivative
chromosome 19 ought be erratic in AML [31,32]. There
is only one case of ALL described, which shows a bal-
anced translocation t(17;19)(q23;p13) as sole abnormal-
ity [33]. Translocations, however, with a breakpoint at
19p13, often with involvement of E2A, have been reported
in approximately 400 cases in AML and in the context of
various fusion partners such as MLL on 11q23 and others
[32]. In an approach to define the breakpoints on the mo-
lecular level in our case we used an E2A (TCF3) specific
break-apart probe for chromosome-band 19p13 and
obtained fusion signals only. This indicated absence of a
chromosomal break within this gene locus (Figure 4).
Therefore, we assume that the breakpoint is located distal
from this locus (D19S883), if not within the sub-telomeric
region. This also precludes other genes within this region
with potential in leukemogenesis, such as MLLT1 or LYL1,
as those are located proximal to E2A. Distal to E2A are
the genes FSTL3 (FLRG), PTBP1 and STK11, and there is
only one report of involvement of FSTL3 with CCND1 in
a case with B-CLL [34].
The band 17q23 has been identified as a “fragile site”
in cancer with higher incidence of chromosomal break-
age [35]. Nevertheless translocations involving 17q23 are
rare in hematologic diseases and have been reported in
AML in only 59 cases, of which 7 cases showed trisomy
8, too. Apart from protein coding genes in 17q23, there
are four miRNA genes (miR-21, miR-301, miR-142s,
miR-142as) located and involvement in neoplastic dis-
eases has been suggested [36,37]. The translocation der
(19)t(17;19)(q23;p13.3) in our case is new and further
studies are warranted to unveil the potential involve-
ment of genes in this unbalanced translocation. The
underlying molecular event could have provided a prolif-
erative advantage to the cells or assisted in genomic in-
stability, since der(19)t(17;19)(q23;p13.3) was eventually
found duplicated in the predominant clone.
AMLs with mutated NPM1 harbour chromosomal ab-
normalities in only about 15% of cases and the most fre-
quent abnormalities are +8, –4 or –Y [38,39]. As
mutated NPM1 is retained during clonal evolution, it is
thought that NPM1 mutations represent a founder mu-
tation, and additional mutations or chromosomal abnor-
malities are thought to be secondary. In our case the
NPM1 mutation did not change during clonal evolution.
However, as we observed trisomy 8 and der(19)t(17;19)
(q23;p13.3) at diagnosis, it is not clear which of the ab-
normalities conferred the founder.
By using the International Prognostic Scoring System
in AML our case initially classified as “Intermediate-II”,as trisomy 8 is not a favourable prognostic factor, but
does not score as an adverse prognostic factor either
[1,3]. However, the prognostic relevance of der(19)t
(17;19)(q23;p13.3) is not known and, hence, this scoring
was only provisional. At first relapse our case reclassified
as “Adverse”, as the criteria of a complex karyotype were
met with the addition of a fourth chromosome 8 and gain
of i(5)(p10). Tetrasomy 8 has been described as a poor
prognostic factor, however, much less information is avail-
able for i(5)(p10) [5,11,13]. On their own, tetrasomy 8 and
i(5)(p10) are frequently part of a complex karyotype and
may reflect genomic instability. Genes located on chromo-
some 8 and 5p may be over-expressed by gene dosage ef-
fects and, thus, could contribute to a possible proliferative
advantage of the cells. In vitro, a proliferative advantage of
tetrasomy 8 over trisomy 8 has been observed in AML
[40]. Cases with either tetrasomy 8 or i(5)(p10) reportedly
show a more aggressive course of the disease, shorter sur-
vival times and poor response to chemotherapy [11,13,25].
Those abnormalities are held as factors of poor prognosis
and our case falls in line with those case reports.
Conclusion
We described the first case of acute monoblastic leukemia
with gain of i(5)(p10), tetrasomy 8, an unbalanced trans-
location der(19)t(17;19)(q23;p13.3) and NPM1 mutation.
During the follow-up of the disease we observed that gain
of i(5)(p10) and tetrasomy 8 represented secondary gen-
etic events in this case. By using the der(19)t(17;19) as
clonal marker we formally demonstrated that tetrasomy 8
has evolved from trisomy 8. This case is only the third, il-
lustrating a step-wise clonal evolution from trisomy 8 to
tetrasomy 8 in AML.
Reporting and collecting data on rare chromosomal
abnormalities of AML will add information to pathogen-
esis, disease progression and prognosis, and may eventu-
ally translate to improved patient management.
Materials and methods
Conventional karyotyping
Bone marrow aspirates were cultured for 24 h and 48 h
in bone marrow culture medium (MarrowMax™, GIBCO,
Paisley, UK). Metaphase chromosomes were prepared
and GTG-banded by standard techniques. A minimum
of 20 metaphases were karyotyped according to the
International System for Human Cytogenetic Nomencla-
ture (ISCN) 2013 [41].
Fluorescence in situ hybridization (FISH)
Polysomy 8 and i(5)(p10) were simultaneously analyzed
by using a probe mixture of the Vysis CEP 8 probe
(D8Z2, SpectrumAqua) and the Vysis LSI 5p/5q Dual
Color probe (EGR1/D5S23,D5S721, SpectrumOrange/
SpectrumGreen, Abbott Molecular, Illinois, USA). The
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with the XL E2A break-apart probe (D19S883/RH98588,
Metasystems, Altlußheim, Germany). Metaphase chro-
mosomes were also analyzed with the 24XCyte multi-
color FISH probe set (Metasystems). All hybridizations
were performed on a ThermoBrite instrument (Abbott
Molecular) with denaturation at 78°C for 2 minutes
followed by over-night incubation at 37°C and subsequent
standard washing procedures, which were completed by
counterstaining with DAPI (4,6 diamidino-2-phenylindole).
For interphase FISH cells from 24 h cultures were used,
and more than 200 nuclei were analyzed. All of the FISH
analyses were performed with a Zeiss Axio-Imager 1 M
fluorescence microscope in combination with the Metafer
4 software (Metasystems).
Mutation analysis
DNA and RNA were prepared from bone marrow aspi-
rates by standard procedures and subjected to NPM1
and FLT3 gene mutation analysis as described [42,43].
Morphology and Immunophenotyping
Peripheral blood cells were examined by an automated
hematologic analyzer (Sysmex, XE-5000, Vienna, Austria).
Bone marrow smears were stained with Wright-Giemsa
and analyzed according to routine clinical laboratory
procedures. Immunophenotyping of bone marrow cells
was performed on an 8-color Navios™ Flow Cytometer
(Beckman Coulter, Germany) according to the manufac-
turer’s instructions.
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